Clinical and technology leaders learning together as AI evolves

Mati Gill, AION Labs CEO, provides an update on the company’s nine AI-enabled drug discovery portfolio companies, how the organizations are making an impact in life sciences and what’s next for AION, including exploring quantum technologies.

Marten den Haring, CEO of Lirio, says the company uses its Large Behavior Model, which blends behavioral science with artificial intelligence, with the goal of driving consumer engagement in healthcare at the personal level.

The U.S. Food and Drug Administration's validation requirements process for drug development is a good model for healthcare artificial intelligence governance, explains Michael Abrams, managing partner at Numerof & Associates.